Lexicon Pharmaceuticals Raises $94.6 Million to Advance Drug Pipeline in Neuropathic Pain and Hypertrophic Cardiomyopathy
Key Insights
Lexicon Pharmaceuticals completed a $94.6 million financing through a public offering and concurrent private placement, pricing 32 million shares at $1.30 per share.
The company plans to use proceeds to fund continued research and development of drug candidates targeting neuropathic pain (search), hypertrophic cardiomyopathy (search), obesity (search), and metabolic disorders.
Invus L.P. (search), Lexicon's largest stockholder, participated in the private placement through its affiliate, purchasing both common stock and convertible preferred shares.
Lexicon Pharmaceuticals has successfully raised approximately $94.6 million through a combined public offering and private placement to fund the continued development of its drug pipeline targeting neuropathic pain (search), hypertrophic cardiomyopathy (search) (HCM), obesity (search), and metabolic disorders.
Financing Structure and Terms
The Texas-based biopharmaceutical company priced its underwritten public offering of 32 million shares at $1.30 per share, generating gross proceeds of $41.6 million before underwriting fees and expenses. The public offering is expected to close on February 2, 2026, subject to customary closing conditions.
Concurrently, Lexicon executed a private placement with an affiliate of Invus L.P. (search), its largest stockholder, for approximately $53 million in aggregate gross proceeds. The private placement includes 22.4 million shares of common stock at $1.30 per share and 367,145 shares of Series B Convertible Preferred Stock at $65.00 per share, which are convertible into approximately 18.4 million shares of common stock.
The underwriters, led by Jefferies (search) and Piper Sandler (search) as joint book-running managers, have been granted a 30-day option to purchase up to an additional 4.8 million shares. H.C. Wainwright & Co. (search) is serving as lead manager for the public offering.
Strategic Use of Proceeds
Lexicon intends to allocate the net proceeds from both the public offering and private placement to fund continued research and development of its drug candidates across multiple therapeutic areas. The company's pipeline includes candidates in discovery and clinical and preclinical development stages, focusing on neuropathic pain (search), hypertrophic cardiomyopathy (search), obesity (search), metabolism, and other indications.
Additional funds will support working capital and general corporate purposes as the company advances its mission of pioneering medicines that transform patients' lives.
Investor Participation
The private placement structure reflects Invus L.P. (search)'s continued commitment to Lexicon, with the investment made pursuant to preemptive rights under Lexicon's Sixth Amended and Restated Certificate of Incorporation. The Private Placement Purchaser also has the option to purchase additional convertible preferred shares on a pro rata basis if the underwriters exercise their option to purchase additional common stock.
Regulatory Framework
The public offering was conducted under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on August 2, 2024, and declared effective on August 15, 2024. The securities offered in the concurrent private placement were not registered under the Securities Act of 1933 and are being issued under applicable exemptions from registration requirements.